Vontobel Holding
ALXN

Vontobel Holding’s Alexion Pharmaceuticals ALXN Stock Holding History

Vontobel Holding’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,758
Closed -$508K – 1250
2021
Q2 		$508K Sell
2,758
-1,271
-32% -$218K ﹤0.01% 756
2021
Q1 		$615K Sell
4,029
-13,578
-77% -$2.1M ﹤0.01% 624
2020
Q4 		$2.72M Buy
+17,607
New +$2.26M 0.02% 360

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Vontobel Holding's ALXN Position: Q3 2021 in Review

Vontobel Holding sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,758 shares — an estimated $508K sold.

Vontobel Holding first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $2.72M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Vontobel Holding reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Vontobel Holding sold 2,758 Alexion Pharmaceuticals shares in Q3 2021, an estimated $508K.
  • Vontobel Holding first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Vontobel Holding's Alexion Pharmaceuticals position peaked at $2.72M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Vontobel Holding's 13F filing for Q3 2021, filed 29 Oct 2021.